Table A2.
Application to Jit et al. (2008) [37].
| a) Inputs | Reported? | Reported by age? (Y/N) | Reported by sex? | Comments |
|---|---|---|---|---|
| Vaccine uptake | Y | Y | Y | |
| Vaccine efficacy | Y | Y (implicitly) | Y (implicitly) | Assumed 100% independent of sex and age |
| Vaccine duration and waning | Y | Y (implicitly) | Y (implicitly) | Assumed independent of sex and age |
| Vaccine and delivery costs | Y | Y | Y | |
| Pre-vaccination disease burden (including PAFs) | Y | Y | Y | In accompanying paper (Jit et al., 2010; Choi et al., 2010) |
| Heterogeneity in sexual behaviour | Y | Y | Y | Reported by age, sex and risk group (Choi et al., 2010) |
| Duration of natural immunity |
Y |
Y |
Y |
|
| b) Outputs |
||||
| Absolute reductions in HPV infections, cervical and other HPV-related cancers and/or warts, post-vaccination | Y | N | Implicitly (cervical) N (warts/non-cervical cancers) |
Outputs considered: cervical (F); warts (F + M); non-cervical cancers (F + M; sensitivity analysis) |
| Absolute reductions in CIN2+ post-vaccination | Y | N | Y (implicitly) | |
| Absolute reductions in invasive cancer post-vaccination | Y | N | Y(Implicitly) |
F: female; M: male; N: no; PAFs: population attributable fractions; Y: yes.